Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
Open Access
- 1 January 2009
- journal article
- review article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2009, 1-12
- https://doi.org/10.1155/2009/896407
Abstract
The epidermal growth factor receptor- (EGFR-) directed antibody, cetuximab, was FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 2006. Additional EGFR-targeting agents in clinical development for SCCHN include other EGFR-directed antibodies, tyrosine kinase inhibitors and antisense DNA. Although the majority of SCCHN overexpress EGFR, SCCHN clinical responses to EGFR-targeting agents have been modest. Molecular predictors for SCCHN response to EGFR-targeted therapies have not been identified. However, molecular correlate studies in lung cancer and colon cancer, which have EGFR-targeted therapeutics FDA-approved for treatment, may provide insights. We describe candidate predictive markers for SCCHN response to EGFR-targeted therapies and their prevalence in SCCHN. Clinical response will likely be improved by targeted therapy combination treatments. Src family kinases mediate EGFR-dependent and -independent tumor progression pathways in many cancers including SCCHN. Several Src-targeting agents are in clinical development for solid malignancies. Molecular correlate studies for Src-targeting therapies are few and biomarkers correlated with patient response are limited. Identifying SCCHN patients who will respond to combined EGFR- and Src-targeting will require further characterization of molecular correlates. We discuss rationale for EGFR and Src co-targeting for SCCHN treatment and describe recent clinical trials implementing combined Src- and EGFR-targeted therapeutics.Keywords
Funding Information
- National Institutes of Health (P50 CA097190-06, R01 CA77308)
This publication has 85 references indexed in Scilit:
- Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cellsCancer Immunology, Immunotherapy, 2009
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- Kras regulatory elements and exon 4A determine mutation specificity in lung cancerNature Genetics, 2008
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsBritish Journal of Cancer, 2008
- The Catalogue of Somatic Mutations in Cancer (COSMIC)Current Protocols in Human Genetics, 2008
- Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsClinical & Experimental Metastasis, 2008
- Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patternsCarcinogenesis: Integrative Cancer Research, 2007
- Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activationProceedings of the National Academy of Sciences of the United States of America, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004